Integrated microbial biologics development and manufacturing
Agilent Advanced Therapeutics provides end-to-end microbial fermentation development and manufacturing for complex biologics, metabolites, and small-molecule intermediates. Our integrated model unifies strain and process development, analytical characterization, scale-up, and cGMP-aligned production across stainless steel and single-use systems. With ICH-aligned quality, robust tech transfer, and deep expertise in <i>E. coli</i> and yeast fermentation, we reduce risk and accelerate progression from early development through commercial supply, supporting reliable, high-quality outputs at every stage.
Flexible bioreactor network—Stainless steel and single-use systems for diverse biologics.
Automated process control—Real-time monitoring for tight control of critical parameters.
High-density fermentation—Optimized strategies to maximize cell mass and productivity.
Broad microbial expertise—<i>E. coli</i>, yeast, and other systems for proteins and enzymes.
Integrated upstream–downstream—Seamless handoff into purification to maintain efficiency.
Accelerated tech transfer—Rapid onboarding and scale-up to GMP manufacturing.
Microbial Fermentation
GMP microbial fermentation for proteins, enzymes, and intermediates with seamless tech transfer and scale-up.
Can you transfer an existing microbial process to your facility?
Yes, we perform structured tech transfer with engineering runs and comparability testing.
style
id
faqs
Browse the latest news on Advanced Therapeutics manufacturing
BIOVECTRA Is Honored with 2025 CDMO Leadership Award
BIOVECTRA, a part of Agilent Technologies Inc., proudly announces it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the category of biologics. The award recognizes BIOVECTRA’s performance in key areas such as quality, reliability, and technical capability.
3/6/2025
Agilent Completes Acquisition of BIOVECTRA
Agilent Technologies announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.
9/20/2024
Agilent Investing $725 Million to Expand Nucleic Acid-Based Therapeutics Manufacturing
Agilent Technologies is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1 billion market and strong demand for the company’s high-quality active pharmaceutical ingredients (APIs).
1/10/2023
id
news
Innovative sustainability in water, waste, and energy
The Frederick facility integrates sustainable practices, like closed-cell cooling towers and reverse osmosis systems that save over 16 million gallons of water annually. A solar photovoltaic array generates 500 MWh of clean energy to offset utility demand. Waste reduction initiatives include acetonitrile recovery and destruction of dilute organics.
id
sustainability
Need help? Contact our support team
Explore more ways to connect with our experts.
Have questions or need a quote? Our manufacturing experts are here to help.
Get support from experienced specialists dedicated to your program’s success.
Upcoming events
See where the Agilent Advanced Therapeutics team will be next. Explore our upcoming conferences, tradeshows, and speaking engagements, and connect with us in person.
